Synapse - Komal Jhaveri

Results (202)

Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study

Meeting Abstract

Bhave, M. A.; Jhaveri, K. L.; Kaufman, P. A.; Aftimos, P. G.; Lombard, J. M.; Sideras, K.; Im, S. A.; Ma, C. X.; Lee, K. T.; Kim, S. B.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2- breast cancer (BC)

Meeting Abstract

Juric, D.; Patel, M. R.; Duska, L. R.; Jhaveri, K. L.; Henick, B. S.; Matulonis, U. A.; Munster, P. N.; Birrer, M. J.; Moore, K. N.; Curigliano, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

Meeting Abstract

Andre, F.; Hamilton, E. P.; Loi, S.; Anders, C. K.; Schmid, P.; Stroyakovskiy, D.; Villanueva, R.; Pedrini, J. L.; Doval, D. C.; Zurawski, B.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer

Meeting Abstract

Mayer, E. L.; Jhaveri, K. L.; Hamilton, E. P.; Kalinsky, K.; Constanzo, J. D.; Rosenthal, K. M.; Spring, L.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US

Meeting Abstract

Razavi, P.; Ahmed, M.; Roush, A.; Parikh, R.; Hitchens, A.; Shen, S.; Safonov, A.; Jhaveri, K. L.; Robson, M. E.; Peacock, N. W.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer

Meeting Abstract

Ferraro, E.; Moiso, E.; Safonov, A.; Cabel, L.; Loudon, L.; Dang, C. T.; Shen, S.; Jhaveri, K. L.; Robson, M. E.; Chandarlapaty, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach

Meeting Abstract

Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer

Meeting Abstract

Shen, S.; Safonov, A.; Bromberg, M.; Chen, Y.; Ahmed, M.; Razavi, P.; Jhaveri, K. L.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): Patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial